ABSTRACT An impaired glucose metabolism, which often leads to the onset of diabetes mellitus (DM), is a common complication of chronic exposure to exogenous and endogenous glucocorticoid (GC) excess and plays an important part in contributing to morbidity and mortality in patients with Cushing syndrome (CS). This article reviews the pathogenesis, epidemiology, diagnosis, and management of changes in glucose metabolism associated with hypercortisolism, addressing both the pathophysiological aspects and the clinical and therapeutic implications. Chronic hypercortisolism may have pleiotropic effects on all major peripheral tissues governing glucose homeostasis. Adding further complexity, both genomic and nongenomic mechanisms are directly induced by GCs in a contextspecific and cell-/organ-dependent manner. In this paper, the discussion focuses on established and potential pathologic molecular mechanisms that are induced by chronically excessive circulating levels of GCs and affect glucose homeostasis in various tissues. The management of patients with CS and DM includes treating their hyperglycemia and correcting their GC excess. The effects on glycemic control of various medical therapies for CS are reviewed in this paper. The association between DM and subclinical CS and the role of screening for CS in diabetic patients are also discussed.
C hronic exposure to glucocorticoid (GC) excess [defined as Cushing syndrome (CS)], whether endogenous or exogenous, reportedly induces hyperglycemia (-).
Exogenous CS is a relatively common condition because almost % of the general population takes GCs for their beneficial properties in the treatment of numerous clinical conditions. Endogenous CS is a rare clinical condition that may be adrenocorticotropic hormone (ACTH) dependent (pituitary adenoma, referred to as Cushing disease, or ectopic ACTHproducing tumors) or ACTH independent (adrenal adenoma, carcinoma, or hyperplasia). Endogenous hypercortisolism may be present to a mild degree [the so-called subclinical CS (SCS)], as reported in adrenal incidentalomas (AIs), which are common "incidental" findings on abdominal radiological studies (particularly computed tomography/magnetic resonance imaging) performed for reasons other than adrenal diseases.
GC excess may impair glucose metabolism through many complex pathophysiological mechanisms and is associated with varying degrees of glucose intolerance, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and overt diabetes mellitus (DM). Impaired glucose metabolism may be an important contributor to the higher cardiovascular morbidity and mortality in patients with CS. Glucose metabolism disorders should consequently be sought and corrected in these patients, even when their fasting glucose levels are normal, aiming for glycemic control as in diabetic patients.
Pathogenesis of DM in CS
A number of pathophysiological mechanisms underlie GC-induced insulin resistance (IR) and the onset of DM in patients with CS (-). Chronic hypercortisolism may have pleiotropic effects on all major peripheral tissues governing glucose homeostasis Table ) . Adding further complexity to the effects of GCs on glucose metabolism, both genomic and nongenomic mechanisms are directly induced by GCs in a context-specific and cell-/organ-dependent manner. There may also be indirect effects of GCs on peripheral insulin sensitivity and glucose homeostasis through GC-dependent changes in protein and lipid metabolism, as well as GC-mediated impairments in interorgan communication conducted by organderived circulating factors. Finally, the release of endogenous GCs is circadian in physiological conditions, but this feature is lost in CS or with the pharmacological administration of GCs, representing another important mechanism behind altered glucose homeostasis in CS ().
This section focuses on established and potential pathologic molecular mechanisms induced by chronically excessive circulating levels of GCs and affecting insulin sensitivity and glucose homeostasis in various tissues (Fig. ) . 
ESSENTIAL POINTS
· The impairment of glucose metabolism is a common complication of chronic exposure to endogenous and exogenous glucocorticoid (GC) excess, contributing to morbidity and mortality in patients with Cushing syndrome (CS) · Chronic hypercortisolism may have pleiotropic effects on all major peripheral tissues governing glucose homeostasis, leading to increased insulin resistance and decreased insulin secretion, acting through both genomic and nongenomic mechanisms in a context-specific and cell-/organ-dependent manner · The fasting plasma glucose level may be normal in most CS patients with diabetes mellitus (DM); therefore, the use of an oral glucose tolerance test or glycated hemoglobin is suggested for diagnosis · Numerous studies have found a higher prevalence of insulin resistance and impaired glucose metabolism in patients with adrenal incidentalomas as well, especially in patients with subclinical CS · Available data do not support large-scale screening for CS in patients with type 2 DM but may prompt a case-finding approach for hypercortisolism in diabetic patients with suggestive features · Controlling hypercortisolism is the first step in improving glucose metabolism in patients with endogenous CS, while taking into account that some cortisol-lowering drugs may have specific effects on glucose homeostasis as well as on cortisol levels, influencing the outcome of DM · For both exogenous and endogenous CS, there is a dearth of evidence regarding the optimal antidiabetic treatment in patients with altered glucose homeostasis, and recommendations are based largely on current best practice 
GC-induced hepatic metabolic disorders
In the liver, chronic hypercortisolism impairs fasting and postprandial glucose and lipid metabolism. In particular, GCs profoundly alter the hepatic action of insulin, resulting in exacerbated gluconeogenesis and hepatic glucose output (HGO) through both direct and indirect effects on the mechanisms controlling these processes. One of the main actions of GCs in the organism is to transcriptionally regulate GC-responsive target genes involved in energy homeostasis (). GCs bind and activate a superfamily of nuclear receptors [glucocorticoid receptors (GCRs)] that control the transcription of certain genes in a cell-and tissue-specific manner by binding directly to genomic glucocorticoid response elements (GCREs) or by tethering to other DNA-binding transcription factors. In the liver, the aberrant HGO that contributes to hyperglycemia is attributed largely to the transcriptional upregulation of key gluconeogenic enzymes. GCREs are present on the promoter of at least two rate-limiting enzymes involved in gluconeogenesis: phosphoenolpyruvate carboxykinase () and glucose--phosphatase (GP) (). The precise mechanisms behind the upregulation of these enzymes by GCs are complex, however, and require the cooperation of other transcriptional activators such as PPAR-a, HNF-, HNF-, and FOXO (, ).
The transcriptional activity of GCRs can also be positively modulated by other transcriptional coactivators, including CBP/p, PGCa, LXRb, MED, and SRC (-), or it can be inhibited by corepressors such as SMAD or LXRa/RXR (, , ). This intricate network of factors potentially involved in how GCs regulate gluconeogenic gene expression convincingly illustrates the complexity and context dependence of the effects of GCs in particular tissues and/or on a systemic level.
A second important effect of GCs in the liver is to induce a selective IR that impedes the inhibitory effect of insulin on HGO while preserving the lipogenic effect of the hormone. Consistent with this selective hepatic IR, which allows lipogenesis to proceed, GCs were shown to upregulate IRS messenger RNA (mRNA) expression () and to increase insulinstimulated AKT activation in hepatocytes (). Contrasting with these data, GCs were reported to induce mRNA expression of TRB, an inhibitor of AKT, in FAO rat hepatoma cells and mouse T-L adipocytes (, ). TRB expression was not increased by GCs in rat primary hepatocytes or L myotubes, however, and TRB overexpression did not affect insulin-induced AKT activation (, ). GC-induced FOXO upregulation also seems to have an important role in the paradoxical GCinduced stimulation of both HGO and lipogenesis. GCs trigger the FOXO-dependent expression of MAP kinase phosphatase- (MKP-), an activator of hepatic gluconeogenesis (), but also of peroxisome proliferator-activated receptor g (PPARg), FAS, SCD, and ACC, which synergistically promote lipid accumulation in hepatocytes (). GC-induced steatosis in rodents also appears to depend on complex transcriptional regulatory mechanisms that involve GCR interactions with other transcription factors, such as LXRb () and MED (), and the repression of genes favoring lipolysis, such as Hes (, ). Surprisingly, only % of patients with CS developed hepatic steatosis (, ), suggesting that lipotoxicity associated with aberrant lipid storage in hepatocytes is not a predominant pathologic mechanism of IR in this disease. On the other hand, it may be that de novo synthesized lipids are rapidly metabolized to toxic intermediates such as ceramides, which are wellknown inducers of IR in the liver and other peripheral organs (). Supporting this hypothesis, dexamethasone stimulates ceramide biosynthesis in rat livers by inducing the expression of several related genes (e.g., Spt, Lass, Lass, Gcs, and Ac), and this is accompanied by glucose intolerance, which can be reversed by a ceramide biosynthesis inhibitor (e.g., myriocin) ().
Interestingly, recent studies indicate that GCs may also stimulate lipogenesis in the liver through epigenetic mechanisms involving microRNAs. In this regard, GCs induced miR- expression in mouse and human livers, and miR- levels correlated with GC and triglyceride levels in obese human patients. The main effects of miR- in hepatocytes seemed to occur on low-density lipoprotein receptors, mediating hepatic triglyceride uptake, and lipolysis-stimulated lipoprotein receptors (). GCs also downregulated miR- (). The downregulation of miR- with obesity was shown to impair insulin sensitivity, enhance glucose production, and increase fatty acid synthesis in the liver. Several key regulators of hepatic metabolism and insulin signaling are among the likely targets of miR- (e.g., Acsl, Acsl, Gskb, Pkcd, Pkcq, Pck, and Tcfl) ().
Increasing attention is being paid to the potential metabolic action of GCs mediated by the regulation of AMP-activated protein kinase (AMPK), a crucial energy sensor that may contribute to increased appetite and adiposity as well as to liver and cardiac dysfunctions associated with CS (, ). In vitro and in vivo studies indicate that AMPK activity was inhibited in adipose tissue and the heart but was stimulated in the liver and hypothalamus (). The role of AMPK in GC-induced changes in hepatic glucose metabolism is supported by the finding that dexamethasone-induced hepatic gluconeogenesis was reduced in rats treated with the AMPK activator AICAR ().
Finally, in humans (as in animal models), chronic hepatic exposure to GCs led to a positive feedback loop on the expression of hepatic b-hydroxysteroid dehydrogenase type  (b-Hsd), the enzyme that reduces circulating cortisone to cortisol (). This vicious cycle, in which excess circulating GCs further increase the production of the active form of cortisol in the tissues, probably exacerbates the deleterious metabolic effects of GCs (). Surprisingly, genetic mouse models of b-Hsd deletion in the liver suggest that high circulating levels of GCs synthesized by other tissues (e.g., adipose tissue) are not enough to trigger metabolic syndrome in mice, pointing to a crucial role for the liver in GC-induced systemic metabolic disorders ().
GC-induced alterations of glucose metabolism in skeletal muscles
Together with hepatic IR, muscle IR and impaired glucose uptake are primary defects that occur before b-cell failure and hyperglycemia develop in DM. Skeletal muscles are major glucose consumers, accounting for % to % of the body's glucose use, and both insulin-dependent and insulinindependent mechanisms promote glucose uptake in muscles. With CS or GC-based therapies, the skeletal muscle has been the only insulin-sensitive tissue to show a clear phenotype in most studies to date. In addition to the well-characterized proteolysis and loss of muscle mass resulting from overexposure to GCs (), a lower muscle insulin responsiveness and impaired glucose uptake has repeatedly been observed (). The precise mechanisms underlying these pathologic GC-induced outcomes in muscle are still not entirely clear, but they too appear to stem from pleiotropic effects that contribute to impairment of insulin signaling and glucose uptake.
As seen in human primary myotubes and CC mouse myotubes, GCs counteract the action of insulin by inhibiting glucose uptake and glycogen synthesis in various ways (-). GC-dependent transcriptional alterations of the genes involved in muscle glucose homeostasis seem, once again, to have a major role. Among more than  genes controlled by GCs in CC mouse myotubes, at least nine (i.e., pa, Ddit, Sesn, Sorbs, Cblb, Pid, Grb, Mknk, and Depdc) had the potential to antagonize the action of insulin (). Of particular interest is the GC-induced overexpression of the palpha subunit of PIK, which was associated with the GC-dependent inhibition of AKT "Several reports suggest that glucocorticoids can activate proapoptotic proteins, repress antiapoptotic proteins, and sensitize b-cell death induced by stress."
and p S kinase activity and with the negative regulatory phosphorylation of IRS (). Some studies have also shown the importance of the GC-induced upregulation of pyruvate dehydrogenase kinase  (Pdk), which inhibits glucose oxidation (, ). Other critical metabolic transcriptional regulators of protein and glucose metabolism are also dysregulated by GCs in muscles, including FOXO and FOXO (shown to promote protein degradation) and C/EBPb (which activates the transcription of myostatin, an inhibitor of AKT in muscles and in other peripheral organs) (, , ).
Impaired insulin signaling through nongenomic mechanisms is also likely to be among the main effects of GCs in muscle cells. GCs impair the activation of the insulin receptors IRS- and PIK in rat muscle cells in vivo and in vitro, thereby preventing full AKT activation in response to insulin (-). Not surprisingly, key downstream AKT effectors controlling glucose uptake and storage are also affected in various muscle cell models exposed to GCs. In particular, translocation to the membrane of the insulin-dependent glucose transporter  (GLUT) is reduced by GCs (), whereas activation of GSK, a repressor of glycogen synthase, is increased (, ). Reminiscent of what happens in the liver, GCs also influence insulin-independent mechanisms that govern glucose uptake, as suggested by studies showing impaired AMPK and TBCD activation in cardiac and skeletal muscle cells chronically exposed to GCs (-).
Other effects associated with chronic hypercortisolism may indirectly influence insulin sensitivity in muscle. In particular, GC-dependent muscle proteolysis raises the intracellular concentrations of amino acids, which can inhibit IRS proteins and PIK activation, thereby contributing to postreceptor insulinsignaling defects (). Dyslipidemia caused by increased GC-dependent lipolysis in fat () may also indirectly affect insulin sensitivity by giving rise to ectopic fat in muscle (). Whether the lipotoxicity and defective insulin signaling resulting from aberrant accumulation of intramyocellular lipid droplets are due only to the formation of toxic lipid intermediates such as diacylglycerol or ceramides is still debated (), but higher ceramide levels in muscle have been associated with GC-induced muscle IR ().
Consequences of hypercortisolism on adipose tissue
Unraveling the molecular mechanisms by means of which chronic hypercortisolism affects glucose homeostasis by changing adipose tissue biology is an intricate and complex issue. In addition to profoundly affecting adipose tissue biogenesis, acutely or chronically high GC levels have various pleiotropic effects on different fat depots (). In patients with CS, the main outcomes of GC-dependent dysregulated adipose physiology are clear, however, and consist of abdominal obesity and high circulating levels of free fatty acids and triglycerides (, ).
Abdominal obesity is closely associated with metabolic syndrome and CS. Lipid overloading of adipocytes in visceral adipose tissue favors the onset of peripheral IR and DM by promoting altered insulin signaling in adipocytes, increased lipolysis, aberrant adipokine secretion, and low-grade inflammation. It is noteworthy that although the low-grade inflammatory state resulting from central obesity is a key driver of obesity-associated IR (), its importance in IR/DM associated with CS is unclear because it may be counteracted by the anti-inflammatory action of GCs ().
GCs act synergistically with insulin in the fed state to enhance de novo lipogenesis. In human and rat adipose tissue, GCs were shown to drastically increase the expression of important genes, most of them bearing GCREs, involved in lipogenesis (e.g., Acc, Fas, Scd, and Gpat) (-). On the other hand, when the activity of important lipogenic genes (i.e., Acly, Fas and Gpd) was assessed in rats, it was increased only in mesenteric fat, not in subcutaneous adipose tissue ().
Dyslipidemia, resulting mostly from lipolysis in fat and from triglyceride secretion by the liver, contributes strongly to the onset of IR and DM by promoting ectopic fat accumulation and lipotoxicity in peripheral organs. Acute exposure to GCs was shown to promote lipolysis in adipocytes in vitro (), a finding consistent with reports of GCs inducing the expression of key lipases in adipocytes such as HSL, desnutrin, ATGL, and MGLL (, -). In addition to the lack of HSL inhibition potentially caused by an insulin-signaling impairment, another mechanism may lie in the direct induction by GCs of angiopoietinlike  (ANGPTL), which increases adipocyte lipolysis (-). These data should be considered with caution, however, because in vivo studies have generated controversial results concerning whether lipolysis is abnormal in patients with CS (, ).
Along with their hypertrophic effect on particular fat depots, GCs also appear capable of inducing the differentiation of preadipocytes, both in vitro and in vivo. Interestingly, the action of GCs on preadipocyte differentiation is specific to visceral (not subcutaneous) fat in rats, and it involves the GC-specific induction of several master transcriptional factors, including Ppar-g, Klf, and Dexras (, ).
The differential effects of GCs on visceral and peripheral fat depots remain poorly understood but are probably responsible for the characteristic fat redistribution from the periphery to the abdomen seen in patients with CS. Lipogenic processes appear to be favored by GCs in visceral fat, whereas lipolysis is promoted in the periphery (, , ). This particular feature is associated with a higher cortisol production in visceral adipose tissue, in which GCs specifically increase the expression of their own receptors and of b-Hsd in positive feedback loops (-). Nongenomic mechanisms implicating a depot-specific GC-mediated inhibition of AMPK activation were also reported in patients with CS, suggesting another mechanism capable of explaining the specificity of visceral fat accumulation in this disease ().
Mechanisms affecting insulin signaling in adipocytes chronically exposed to GCs are also depot specific. Although hydrocortisone induces a systemic IR in humans, subcutaneous adipose tissues remain insulin sensitive and even have enhanced expression of IRS and insulin-stimulated Akt, two features not seen in omental adipose tissue (). In contrast, administering dexamethasone in rats inhibited IRS and AKT activation in response to insulin in visceral epididymal fat (), whereas in mice the same effects were observed in both subcutaneous and epididymal fat as well as in cultured mouse TL preadipocytes (). The precise mechanism by which GCs impair insulindependent AKT activation in adipocytes is still not clear, but recent evidence indicated that the GC-mediated expression of the AKT-negative regulator FK-binding protein (FKBP) might be involved in these processes in both omental and subcutaneous human adipose tissues (-). Corticosterone also markedly raised the levels of circulating plasminogen activator inhibitor- (PAI-) in mice, and the highest increase in PAI- mRNA levels was found in the white adipose tissue (). The same study showed that PAI- inhibited insulin-induced AKT phosphorylation and glucose uptake in hepatocytes, pointing to potential paracrine effects of PAI- on adipocyte insulin sensitivity ().
Finally, the dysregulated expression and secretion of other important adipokines regulating insulin sensitivity and glucose homeostasis in the periphery have been shown to result from the chronic exposure of adipose tissue to high GC levels. In particular, greater expression and secretion of leptin (, ) and resistin () and lesser expression and secretion of apelin () were associated with abdominal obesity in patients with CS. Whether GCs alter the expression and secretion of adiponectin (one of the most important insulin-sensitizing adipokines) in patients with CS is still controversial ().
Effects of GC on pancreatic endocrine functions IR progresses to overt DM when the pancreatic b-cells can no longer compensate for peripheral IR by increasing b-cell function and insulin secretion. Acute or chronic GC administration appeared to impair different aspects of b-cell function in a dose-dependent manner (). An early event induced by GCs is a rise in b-cell mass and insulin production as a result of adaptive mechanisms of the endocrine pancreas to compensate for GC-induced IR (). With time, however, chronically high circulating GC levels have a negative effect on b-cell function and adaptation to IR. In patients with CS, glucose intolerance was associated with inadequate compensation of insulin secretion by b-cells (, , , -), but whether it is the function and/or the mass of b-cells that is altered by GCs remains to be seen. In this regard, studies on the overexpression of GCR in b-cell precursors or mature b-cells indicated that aberrant GC signaling affected b-cell mass when it occurred in precursor cells, whereas excessive GC signaling in mature b-cells affected their function and caused glucose intolerance (, ). It is interesting that b-cell function-and basal oscillatory insulin release in particular-was also perturbed by administering prednisolone to healthy men in a fasting state (). The expression and stability of the GLUT transporters, impaired glucose oxidation, oxidative stress, decreased Ca + signaling responses, and increased voltage-gated K + channel activity have also been reported to contribute to impaired insulin secretion by b-cells on exposure to GCs (-). Finally, epidemiological studies in a Japanese cohort indicated that GCinduced DM is associated mainly with IR and/or b-cell dysfunction, not with a decrease in b-cell mass, supporting a key role for the loss of b-cell function (rather than b-cell mass) in CS ().
Although a deleterious effect of GCs on b-cell mass remains controversial, several reports suggested that GCs can activate proapoptotic proteins, repress antiapoptotic proteins, and sensitize b-cell death induced by metabolic and inflammatory stress (). GCs reportedly triggered proapoptotic mechanisms through at least three different pathways: overexpression of thioredoxin-interacting protein (TXNIP; a negative regulator of the antioxidant thioredoxin) (), stimulation of mitogen-activated protein kinases such as p and JNK (), and unfolded protein response (). The GC-mediated induction of the antiproliferative factor MIG, which reduces ERK/ activation and thereby blocks G()/S cell cycle transition, is another mechanism potentially contributing to the decrease in b-cell mass associated with excessive exposure of b-cells to GCs ().
Finally, the function of other pancreatic islet cells, which may counteract insulin action and/or secretion by b-cells, is also disturbed by chronic GC exposure (, ). For example, dexamethasone was reported to induce hyperglucagonemia in rats and macaques by increasing a-cell mass and/or glucagon release (-). The expression of somatostatin (SST) by d-cells, which has negative regulatory effects on insulin and glucagon secretion, is also increased in rats chronically administered dexamethasone, though it remains unclear whether SST secretion increases or not (). In rats and humans, dexamethasone was also found to stimulate the secretion of amylin in b-cells, which can then form toxic amyloid aggregates and cause b-cell apoptosis in humans (-). Lastly, the levels of ghrelin, a hormone that stimulates the appetite, inhibits insulin secretion, and increases glucagon secretion, were lower in patients with CS or treated with prednisolone (). Whether the effects of GCs on ghrelin secretion occurred in the «-cells of the islets or in the stomach cells that produce the bulk of ghrelin is currently unknown, however.
Contributions of the gut, bones, brain, and growth hormone/insulinlike growth factor 1 axis to GC-induced changes in glucose metabolism Increasing evidence has recently suggested hitherto unexpected roles for other organs in the altered "Cushing syndrome patients with diabetes mellitus…reveal a baseline defect in b-cell secretory responsiveness that may be partially reversible." systemic glucose homeostasis induced by chronically high GC levels.
Incretins are hormones secreted by the digestive tract that potentiate insulin secretion by b-cells in response to high postprandial plasma glucose concentrations. Among them, glucagonlike peptide- (GLP-) secreted by L cells in the ileum and glucose-dependent insulinotropic polypeptide (GIP) secreted by K cells in the duodenum are the main insulinotropic factors identified to date (). Dexamethasone administration in rats was found to lower GLP- secretion, indicating that not only the effect of incretins on b-cells can be blunted by GCs, but the secretory function of L cells may also be affected (). These results were not reproduced in rhesus macaques treated with dexamethasone, however, which exhibited higher secretion of postprandial GLP- accompanied by lower secretion of GIP, resulting in improved b-cell function (). Finally, two studies in humans suggested that incretin secretion was unaffected by dexamethasone administration, but the insulinotropic effects of these hormones on b-cells were reduced in response to GCs (, ). Further studies are therefore needed to clearly delineate the long-term effects of increased circulating GC levels on incretin secretion by the digestive tract.
Bones have also recently emerged as important regulators of glucose homeostasis (). Excessive and prolonged exposure of bones to GCs in the mouse reportedly suppressed the synthesis and release of osteocalcin, an osteoblast-derived hormone that stimulates insulin sensitivity (-). Further supporting a role for bone-derived osteocalcin in GC-induced IR, the deleterious effects of GCs on peripheral insulin sensitivity were attenuated by deletion of the GCR in osteoblasts or osteocalcin overexpression in the liver (, ). Bone expression of TXNIP, a GC-regulated factor involved in glucose metabolism (, ), was also higher in patients with CS, and its expression correlated with IR. Interesting in vitro experiments showed that conditioned media from TXNIP-depleted osteoblasts were able to increase the insulin content of human b-cells ().
GC signaling in the brain appears to influence peripheral metabolism as well, either by releasing signaling peptides into the circulation or through the nervous system. In vivo experiments in rats revealed that GCs strongly promoted the expression of the orexigenic factor neuropeptide Y in neurons from the arcuate nucleus, thereby promoting IR in the liver-an effect mediated by the sympathetic nervous system (). Involvement of the central nervous system in GC-mediated peripheral IR was supported by another study showing that hepatic vagal innervation was required for GC-induced metabolic disorders ().
It is also worth noting that the action of GCs may be influenced by GCR (NRC) polymorphisms (), some of which have been shown to impair GC sensitivity and may be associated with altered metabolic profiles. In particular, the AG GCR polymorphism seems to have a protective role in patients with CS, attenuating the effects of GC excess on their glucose metabolism and reducing the risk of DM (), whereas the Bcl polymorphism in intron  of GCR has been linked to hyperinsulinemia, IR, and obesity (-). How GCR polymorphisms affect GC signaling and metabolic homeostasis in specific insulin-sensitive and -insensitive tissues remains to be elucidated, however.
GC-induced changes in growth hormone (GH) secretion and circulating levels of insulinlike growth factor  (IGF-) can also contribute to the defective glucose metabolism seen in CS. Excessive or deficient GH secretion substantially affects the amount of fat stored in visceral depots, lipidemia, hepatic and muscle IR, and insulin secretion from b-cells (, ). IGF- is produced mainly by the liver in response to GH stimulation, and it triggers insulinlike metabolic effects because of its structural similarity to insulin and capacity to activate the same receptor and signal transduction pathways. Consistent with this action, low circulating IGF- levels have been associated in numerous studies with reduced insulin sensitivity, glucose intolerance, and DM (). In vitro and in vivo studies have indicated that GH secretion can be either stimulated or inhibited, depending on GC concentrations and time of exposure [for comprehensive reviews, see
Such a biphasic effect of GCs on GH secretion emerged in human studies as well (). At the molecular level, an acute increase in GH levels was found to occur via activation of the MAP kinase pathway and the transcription factor ELK, which targets the GH promoter (). Chronic hypercortisolism, on the other hand, probably inhibits GH secretion by disrupting the SST axis (). In patients with CS, GH secretion in response to various stimuli was severely repressed because of the chronic effects of hypercortisolism. It is likely that GH/IGF- deficiency is an important contributor to growth retardation and low stature in children with CS, in conjunction with other GH-independent effects associated with hypercortisolism (). In adults, an impaired GH/IGF- signaling axis probably exerts its deleterious effect mainly on insulin sensitivity and lipid/ glucose metabolism (, , -). Because GH and/ or IGF- appeared to inhibit a key enzyme involved in cortisol metabolism (i.e., b-Hsd) (), GH/IGF- deficiency may further promote hypercortisolism and its deleterious effects on glucose metabolism in a vicious cycle. To what extent the GH/IGF- axis alterations contribute to IR and impaired glucose metabolism in CS remains to be clearly established, however.
GC metabolic effects mediated by mineralocorticoid receptors
Cortisol excess may also influence glucose metabolism through its action on mineralocorticoid receptors (MRs). In fact, MRs have a similar affinity for aldosterone and cortisol (), but GCs circulate at -to -fold higher plasma concentrations than does aldosterone. Corticosteroid-binding globulin binds cortisol with a high capacity and affinity, reducing free GC levels tõ %, whereas aldosterone circulates mainly in its free form (). In classic aldosterone target tissues, such as the distal parts of the nephron and colon, the enzymatic breakdown of cortisol to cortisone by -beta hydroxysteroid dehydrogenase type  (b-Hsd), which has no affinity for MRs, allowed for aldosterone to specifically bind to and activate MRs (). In other tissues, such as brain and adipose tissue, MRs are considered high-affinity GC receptors, fully occupied by cortisol. In patients with CS, high cortisol levels may saturate the cortisol-inactivating enzyme b-Hsd at the renal tubule level, thus giving intact cortisol access to the MRs. Experimental evidence supports the existence of crosstalk between mineralocorticoid hormones and insulin. Higher plasma mineralocorticoid levels may be associated with IR (, ). In patients with primary aldosteronism (PA), resection of aldosteroneproducing tumors and pharmacological treatment both reduced blood insulin and glucose levels, suggesting an improvement in insulin sensitivity (, ). MR activation impaired insulin metabolic signaling via several putative mechanisms in cardiovascular and renal tissue, as well as in fat, skeletal muscle, and the liver. Campión et al. () demonstrated a reduction in the number of insulin receptors and in insulin receptor gene expression in adipocytes isolated from the subcutaneous tissue of an individual with PA. Mineralocorticoids might also indirectly limit insulin secretion by the pancreas as a result of hypokalemia; in other words, impaired insulin secretion could be caused by potassium depletion in individuals with PA. Several other mechanisms of aldosterone-induced glucose intolerance have been suggested, including effects on insulin signaling, stimulation of hepatic gluconeogenesis, effects on sodium-glucose transport, and fibrosis-induced dysfunction in insulin-producing or insulin-sensitive tissues. It has been suggested that nongenomic actions of MRs might result in increased collagen synthesis and fibrosis, not only in the heart but also in other insulin-sensitive tissues such as the pancreas, liver, fat, and muscle. These mechanisms can lead to tissue damage, potentially resulting in altered insulin release and sensitivity (). In studies demonstrating an association between aldosterone and lower pancreatic b-cell function, serum aldosterone levels were inversely related to C-peptide levels and to the homeostasis model assessment of pancreatic b-cell function (HOMA-b) (). MR activation may exert these detrimental effects on the structural and functional integrity of b-cells by promoting islet cell inflammation and oxidative stress ().
MRs on adipocytes promoted the expression of inflammatory adipokines (-), giving rise to lower insulin receptor expression and impaired insulin-induced glucose uptake (). Similarly, patients with PA had low adiponectin levels with an associated weaker insulin sensitivity (). The adipocyte MRs may mediate a proadipogenic effect of both aldosterone () and GCs ().
Epidemiology of Glucose Metabolism Abnormalities in Cushing Syndrome
The American Diabetes Association defined DM in CS as a "specific type of diabetes secondary to endocrinopathy" (, ).
Endogenous CS
From % to % of patients with endogenous CS have DM, and % to % have defective glucose tolerance, so the overall prevalence of glucose metabolism impairments can come close to %, as shown in Table  (, , -). No sex-related differences have been described in the prevalence of this CS complication (, ). The problem may be underestimated because the presence of DM is not always accurately investigated in patients with CS. Fasting plasma glucose (FPG) level may not suffice to assess glucose homeostasis in CS because more than one in two patients (%) with endogenous CS and DM have normal FGP levels () and because an oral glucose tolerance test (OGTT) is not always performed in patients with apparently normal fasting glycemia ().
Diabetes can develop irrespective of the etiology of cortisol excess in patients with endogenous CS (, ), and its onset does not seem to correlate with the duration of the latter disease (). Generally speaking, the severity of hypercortisolism correlates with the presence of IR and DM, as evidenced by an association with higher urinary free cortisol (UFC) levels (, ), though this was not identified in all studies (, ). This discrepancy is hardly surprising, given wide interindividual susceptibility to the adverse effects of GCs. Age, genetic predisposition, and lifestyle combined with the duration and degree of hypercortisolism strongly contribute to glucose tolerance impairment in patients with CS, as confirmed in a recent study ().
Exogenous CS
The risk of developing DM secondary to exogenous GC administration is difficult to estimate because study populations have very different susceptibility to hyperglycemia, partly owing to varying indications for GC treatment and to patients' different age groups, comorbidities, and genetic factors. GC-induced hyperglycemia or DM is nonetheless a common complication (-), and there are reports of a dose-dependent increase in the risk of developing DM requiring hypoglycemic therapy ().
Nearly % of patients with rheumatoid arthritis developed DM within  years of starting GC treatment (). Among nondiabetic patients with primary renal disease being treated with prednisolone . mg/kg/d, % had plasma glucose concentrations . mg/dL  hours after lunch, but normal fasting glucose levels (). In a case-control study, the odds ratio of starting an oral hypoglycemic agent or insulin was . for patients receiving a hydrocortisone-equivalent dose of  to  mg/d, . for  to  mg/d, . for  to  mg/d, and . for $ mg/d ().
A recent meta-analysis revealed an odds ratio of . to . for newly diagnosed DM in patients taking exogenous GCs; measuring FPG level may underestimate the disease compared with a glucose tolerance test (). The risk of DM was greater in subjects with abdominal adiposity or a genetic predisposition to DM and in those taking higher doses of GCs and for longer periods (, -). Nevertheless, there is evidence of even low supraphysiological doses of GCs (e.g., prednisolone . mg once daily) impairing glucose tolerance when administered chronically ().
Subclinical CS
Numerous studies have found a higher prevalence of IR in patients with AIs, especially in cases with SCS (-). The studies reporting the prevalence of DM or glucose abnormalities in patients with AI are summarized in Table . By definition, AI patients have no clinical signs of abnormal cortisol secretion; however, % to % of them may have SCS. The -mg dexamethasone overnight suppression test is recommended for screening patients with AI for SCS, setting the threshold at  nmol/L; a value of  nmol/L virtually excludes SCS, whereas values between  and  nmol/L occupy an area of uncertainty (). There is no general consensus, however, on the diagnostic criteria for identifying cases of SCS, which consequently vary considerably among different investigators and studies. A chronic mild cortisol secretion abnormality may be associated with classic metabolic and cardiovascular complications of hypercortisolism (, -). Focusing on glucose metabolism, the prevalence of IGT or DM has been higher in patients with SCS than in cases of nonfunctioning adenoma or controls (, , , , , , ), but these data were not confirmed by other studies that found much the same prevalence of these comorbidities in SCS as in the overall series of AI and in the general population (, -).
The varied prevalence of glucose metabolism anomalies in SCS may be due partly to the screening methods used [fasting glucose and insulin vs OGTT or glycated hemoglobin (HbAc)] and partly to the different criteria used across studies to diagnose SCS.
Overall, DM or IGT was identified in % to % of patients with AI and SCS and was related to patients' age (), the size of their adenomas, their midnight cortisol level, and their plasma cortisol level after suppression with dexamethasone ().
The results of these studies suggest that chronic mild hypercortisolism, as in SCS, may be associated with the clinical phenotype of IR syndrome or, alternatively, that AI may be per se an unrecognized manifestation of metabolic syndrome. In fact, it has been demonstrated that insulin is mitogenic, capable of stimulating adrenal cortex cell proliferation and tumor formation in a time-and dose-dependent manner, without affecting cortisol synthesis (, ).
Screening for DM in Patients With CS
Because measurements of fasting glucose levels may underestimate the real prevalence of glucose disorders in patients with endogenous and exogenous hypercortisolism, the OGTT is considered the gold standard for diagnosing impaired glucose metabolism in CS (). HbAc levels $.%, suggested for the diagnosis of DM in the general population, may be particularly helpful in the clinical setting of CS because this parameter is an integrated measure of glucose homeostasis (). Surrogate markers of peripheral insulin activity, such as homeostasis model assessment and whole-body insulin sensitivity indexes, could be useful as well in the early identification of patients with IR, before overt DM sets in (). In addition to HbAc, glycated albumin (GA) has been used as an indicator of glycemic control () over the preceding  weeks. Because GCs are known to promote the catabolism of proteins, including serum albumin (, ), there is a risk that GA levels will be influenced by GC excess. GA levels should therefore be carefully interpreted when diagnosing and treating DM in patients with CS (). Even if their glucose tolerance is normal when their CS is diagnosed, patients should be screened for any subsequent onset of glucose alterations using HbAc assays and/or OGTT. There are no accepted general guidelines on the frequency of such screening for DM, but clinical judgment-based also on risk factors such as obesity, family history, or metabolic syndrome-should prompt regular tests for glucose tolerance anomalies.
Screening for Hypercortisolism in Patients With Type 2 DM
The association between DM and CS has been examined in various studies, which have shown a prevalence of previously unsuspected CS in patients with type  DM ranging from % to .% (Table ) (-). The studies reporting higher rates included patients with features conferring a high probability of CS a priori (e.g., obesity, hypertension, and poor glycemic control). Diagnostic tests and cutoffs are important factors influencing the outcome of any screening. In one of the largest series reported to date (), a frequency of .% of previously unsuspected CS was identified in a cohort of  unselected patients with type  DM. Although this figure is too low in absolute terms to support the efficacy of widespread screening, it means that CS is much more common than previously believed, considering the high prevalence of type  DM in the general population. In addition, the frequency of CS was .% among patients with HbAc levels ..% despite intensive treatment and with blood pressure levels not on target despite the use of three drugs (). These data suggest that most cases of CS may actually go unrecognized because of its phenotypic similarities to metabolic syndrome.
On the other hand, the frequency of CS identified in an unselected population of type  DM patients was too low compared with the number of false-positive results to make a routine screening strategy applicable in practice (), given its high cost-effectiveness and the lack of specific tests for diagnosing CS, especially in patients with a slightly elevated cortisol secretion and SCS (). It is worth noting that no cases of confirmed SCS emerged among a population of  diabetic outpatients forming another large series in a recent study in India (); in this study, however, patients with clinical signs suggestive of hypercortisolism (easy bruising, facial plethora, proximal muscle weakness, and/or striae) were excluded a priori from the evaluation. Conversely, another recent study that involved screening for CS in  "at risk" subjects (i.e., patients attending endocrinology units who had at least two of the following features: obesity, poorly controlled blood pressure, uncontrolled DM, hirsutism with menstrual disorders, osteoporosis) described a prevalence of CS of .% in the whole cohort and % among  diabetic patients ().
Available data consequently do not support largescale screening for CS in patients with type  DM but may suggest a case-finding approach for hypercortisolism in diabetic patients with certain features (i.e., uncontrolled DM despite appropriate treatment, drug-resistant hypertension, Cushingoid appearance, central obesity, osteoporosis, or polycystic ovary syndrome) (, ). A diagnosis of type  DM in patients , years of age should also arouse a suspicion of CS (). A negative family history of DM should also be considered when selecting patients for screening.
Therapeutic Options for CS and Glycemic Control
Controlling hypercortisolism is the first step toward improving glucose metabolism in patients with endogenous CS, but different treatments for hypercortisolism may affect the outcome of diabetes, regardless of how well cortisol excess is corrected (, , , , , , ).
In patients with CD, the recommended first-line therapy is resection of the pituitary adenoma (). The remission rate after neurosurgery is in the range of % to %, with a risk of recurrence at  years ranging between % and %; for macroadenomas, the remission rate is lower, and recurrences tend to occur earlier than for microadenomas (). Radiotherapy may be used as a second-line treatment in patients with persistent or recurrent disease after surgery or when surgery is contraindicated. Both treatments can cause hypopituitarism (including GH deficiency) that, left untreated, may alter glucose metabolism and raise patients' cardiovascular risk (). Bilateral adrenalectomy could be performed as a rescue treatment in patients with persistent and severe disease, but this approach causes permanent adrenal insufficiency and carries the risk of corticotroph tumor progression (Nelson syndrome). Any overtreatment of hypoadrenalism should be avoided in such patients because of its role in exacerbating some persistent complications of CS, such as hyperglycemia (, ). Adrenalectomy is the therapeutic gold standard for patients with adrenal CS caused by functioning adrenal adenomas. This approach also could be proposed for patients with SCS if they are young and/or have comorbidities such as hypertension, DM, and osteoporosis (, ).
The normalization of cortisol levels after surgery and/or radiotherapy is generally followed by the resolution of patients' glucose metabolism impairment because their hypercortisolism is responsible for their hyperglycemia. IR and cardiovascular risks may persist after hypercortisolism has been corrected (, ), however, and treatment of DM may need to be continued even in patients "cured" of their disease. In such cases, the antidiabetic drug dosage should be carefully adjusted to avoid the risk of hypoglycemia consequent to the normalization of cortisol secretion.
As demonstrated by Colao et al. () in , patients cured of CD who have normal serum and 
Medical Therapy for CS and Glycemic Control
Drugs are currently considered a second-or third-line therapeutic approach for patients with CS. Medical therapy may be used preoperatively, after surgery in patients with persistent or recurrent disease, before and after pituitary radiotherapy, while waiting for radiation to take effect, or as first-line treatment mainly in cases in which surgery is contraindicated (because of the patient's poor general condition or refusal of surgery, with ectopic ACTH secretion from a tumor of unknown location, or in cases of widely disseminated metastatic disease). Two different medical approaches can be considered for the treatment of CS: adrenal-directed and pituitary-directed drugs (the latter are used only for CD) (-). The choice of medical therapy may influence the outcome of GC-induced DM because of the specific effects of some drugs on glucose metabolism as well as on cortisol levels (Tables  and ).
The effect of adrenal-directed drugs
The purpose of adrenal-directed medical therapies is to reduce cortisol secretion by the adrenal glands. The therapies most often used or currently under development are ketoconazole, metyrapone, mitotane, etomidate, and LCI. They can be used in every form of CS and may be highly effective in controlling cortisol excess. Ketoconazole, metyrapone, and LCI are dose-dependent, reversible inhibitors of adrenal cortisol synthesis, acting on one or more enzymes responsible for adrenal steroidogenesis (). At doses higher than  g daily, mitotane also has an adrenolytic effect, inducing cellular necrosis, so it is indicated mainly in adrenal cancer (). Ketoconazole Ketoconazole has been used worldwide for more than  years to lower circulating cortisol levels in CS, although only retrospective studies have reported on its use to date.
At doses of  to  mg daily, this steroidogenesis inhibitor has been shown to improve glucose metabolism in patients with CS and in those with type  DM (-). Regarding the latter group, Marin and Birketvedt () examined the impact of  mg of oral ketoconazole daily in  female patients with visceral obesity, IR, and type  DM in a -month randomized, double-blind, placebo-controlled trial to see whether modulating GC processing was a viable approach to the treatment of metabolic syndrome. After  months, there were statistically significant improvements in several risk factors associated with metabolic syndrome (IR, total cholesterol, fasting glucose levels, HbAc levels, and blood pressure) (). In a previously conducted phase a study, treatment with DIO- (an enantiomer S,R of ketoconazole) was associated with a decrease in total and low-density lipoprotein cholesterol and C-reactive protein levels ().
Among the studies involving CS patients, one conducted by Moncet et al. () in  considered  patients treated with ketoconazole at doses of  to  mg/d for a mean of . months (range:  days to  years). Eleven of the  patients (%) had DM at baseline, and eight of them (%) normalized their glucose levels by dieting and taking ketoconazole alone, whereas oral antidiabetic drugs were required in two to achieve normal glucose levels and insulin in one. In , Castinetti et al. () retrospectively assessed  patients with CD treated with ketoconazole  to  mg/d for a median of  months (range:  to  months); all five patients with DM achieved hormonal control associated with metabolic improvement (based on HbAc monitoring and the need for antidiabetic therapy). In another retrospective study by Valassi et al. () on the potential effects of steroidogenesis inhibitors for the presurgical treatment of CS,  patients ( treated with ketoconazole,  with metyrapone, and  with ketoconazole plus metyrapone) were evaluated after a median period of  months (range:  to . months). Eight patients (%) had DM at baseline. HbAc levels dropped in patients whose cortisol levels were controlled or partially controlled, and their doses of oral antidiabetic agents were reduced, whereas a gradual increase in doses of insulin or oral antidiabetic agents was needed in patients with noncontrolled levels. No details were provided on the effects on glycemic control of combining ketoconazole with metyrapone as opposed to their separate use (). More recently, a retrospective multicenter study by Castinetti et al. () reviewed data on  CD patients treated with ketoconazole alone. When ketoconazole treatment was initiated, .% of the patients had DM. Glycemic control improved (in terms of one or more of the following: a .% decrease in insulin dose; a decrease in 
Metyrapone
Metyrapone is a potent, rapid-onset, short-acting cortisol synthesis inhibitor. It takes effect mainly on the final step of cortisol synthesis (the conversion of -deoxycortisol to cortisol by the enzyme b-hydroxylase) (). Various studies, summarized in Table  other cortisol-lowering drugs) in  CS patients, % of them with DM. The effects on glucose metabolism were not analyzed in this study, but hypoglycemia was reported in three patients taking antidiabetic drugs following improvement in their hypercortisolism ().
LCI699 LCI (osilodrostat) has a mechanism of action similar to that of metyrapone; however, it is more powerful against b-hydroxylase [with an in vitro half maximal inhibitory concentration (IC) of . nM vs . nM], and it inhibits aldosterone synthase. It is currently under investigation as a potential new treatment of CS.
An open-label, single-arm, multicenter, proof-ofconcept study was conducted to assess the safety, tolerability, and efficacy of LCI in  patients with CD treated for  weeks (). In terms of its effects on glucose metabolism, three patients with baseline HbAc levels ..% showed decreases of .%, .%, and .% in their HbAc levels, although no significant changes in insulin and HbAc levels were apparent in the group as a whole. A subsequent -week, prospective, open-label, multicenter, phase  study further examined osilodrostat in  patients with CD over a longer period, identifying a large proportion of responders (); in terms of glucose metabolism, there was a drop from baseline to week  in FPG (2. 6 . mg/dL) and HbAc (2.% 6 .%) levels; the improvement in FPG level was greater (2. 6 . mg/dL) in eight of  patients with DM at baseline.
The effect of GCR antagonists

Mifepristone
Mifepristone is a progesterone receptor antagonist that, at higher concentrations, has GCR antagonist activity as well. Because of its rapid onset of effect, it can play a part in the management of CS-especially in cases of severe disease or concomitant conditions requiring prompt control of cortisol excess. This drug was approved by the US Food and Drug Administration in  for the treatment of hyperglycemia in patients with endogenous CS and associated DM or glucose intolerance who are not candidates for surgery.
After the first case reports and small retrospective studies documenting improvements in glucose metabolism and symptoms associated with CS (-), an open-label, prospective, multicenter, -month study (Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing's Syndrome) was conducted in patients with endogenous CS that was refractory to other therapies (). Mifepristone was administered at doses of  to  mg daily for  weeks to  patients with CS,  of them with DM or IGT. The area under the curve (AUC) for glucose on the OGTT dropped by at least % from baseline to week  in % of patients with DM/IGT, with a median decrease of % and with comparable reductions in their plasma glucose levels ().
The OGTT data from the Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing's Syndrome were then analyzed () to assess whole-body insulin sensitivity (Matsuda index) and b-cell function (insulinogenic index, HOMA-b, disposition index) in patients treated with mifepristone. The Matsuda index improved in the total study population, with the greatest improvement occurring between baseline and week  and smaller changes occurring from weeks  to , suggesting a rapid improvement in insulin sensitivity due to the direct effects of GC blockade and a longer-term improvement resulting from weight loss. At baseline, patients with DM had impaired insulin secretory responses (revealed by a lower insulinogenic index and HOMA-b). Nondiabetic patients experienced drops in insulinogenic index and HOMA-b by week , whereas these parameters tended to rise slightly (though not significantly) in DM patients. The disposition index was lower at baseline and showed a non-statistically significant rising trend during the study in patients with DM vs nondiabetic patients (P = .). These data suggest that CS patients without underlying DM experienced appropriate reductions in b-cell secretory response that were proportional to their improved insulin sensitivity, with insulin secretion decreasing in parallel; on the other hand, CS patients with DM revealed a baseline defect in b-cell secretory responsiveness that may be partially retrievable with mifepristone treatment, along with an improvement in insulin sensitivity ().
Another prospective, open-label pilot study was performed in six patients with AIs and autonomous cortisol secretion (defined as failure to suppress serum cortisol to , nmol/L on -mg dexamethasone overnight suppression and -mg/d low-dose dexamethasone -hour suppression testing) who were treated with mifepristone  mg twice daily for  weeks (). Across the group, there were significant improvements in glucose metabolism parameters at  weeks in terms of patients' IR and b-cell function indices: natural logarithm of homeostasis model assessment of insulin resistance (lnHOMA-IR) (. vs .; P = .); of homeostasis model assessment of beta cell function (lnHOMA-%b) (. vs .; P = .); and of Matsuda index (lnMatsuda) (. vs .; P = .). A reduction in the insulin AUC during a -hour glucose tolerance test was seen in five of six patients.
The effect of pituitary-directed drugs
Drugs that directly target the pituitary corticotroph tumor (the primary source of hormone excess in patients with CD) include neuromodulatory agents that take effect mainly on dopamine and SST receptors expressed in the corticotroph cells and ligands of nuclear transcription factors involved in hypothalamic-pituitaryadrenal axis regulation, such as PPAR-g agonists and the retinoic acid receptor agonists.
Dopamine agonists
Dopamine agonists have an inhibitory effect on ACTH secretion mediated by the dopamine receptor D  , which is expressed in more than % of corticotroph pituitary adenomas (). Cabergoline is the most commonly used drug in this class, which can improve glucose tolerance in CD patients not only as a consequence of a reduction in cortisol levels but also by directly influencing glucose homeostasis.
The positive effect of cabergoline on glucose metabolism was suggested by several small, prospective, randomized trials conducted in diabetic and obese patients (-). Bromocriptine (another dopamine receptor agonist) improved glucose homeostasis in type  DM patients, probably by stimulating splanchnic glucose reuptake and facilitating the insulin-mediated suppression of hepatic glucose production (). Much attention has recently been paid to the action of dopamine on glucose homeostasis at central and peripheral levels, impacting both the autonomic nervous system and the endocrine system. Dopamine inhibits prolactin, which has metabolic functions and reduces insulin secretion by pancreatic b-cells. Different central actions of the dopamine system may also mediate its metabolic effects, such as regulation of hypothalamic noradrenaline output, participation in appetite control, and maintainance of the biological clock in the suprachiasmatic nucleus (). There is reportedly an early morning peak in hypothalamic dopaminergic activity in healthy individuals (). The circadian rhythm of dopamine release in the region of the biological clock (i.e., the hypothalamic suprachiasmatic nucleus) has been implicated in the regulation of peripheral insulin sensitivity as well as in glucose and lipid metabolism. A sizable number of studies suggested that a diminishing circadian peak in dopaminergic input facilitated the onset of weight gain, IR, and glucose intolerance, whereas a reversal of the dopaminergic peak resulted in improved insulin sensitivity and glucose tolerance in a variety of animal models of metabolic syndrome and type  DM (). This finding prompted the use of a quick-release formulation of bromocriptine, administered once daily within  hours of waking, to mimic and resynchronize the natural dopaminergic circadian rhythm that may be faulty in diabetic patients. Quick-release bromocriptine has been approved for the treatment of type  DM by the US Food and Drug Administration ().
As for patients with CD, long-term therapy with cabergoline at doses of  to  mg/wk was shown to induce sustained control of hypercortisolism in up to % of cases (). Small trials suggest that combination therapy with ketoconazole increased the effectiveness of this treatment (, ). Cabergoline has also reduced the prevalence of DM and glucose intolerance by % and %, respectively, irrespective of whether hypercortisolism was controlled or not. Pivonello et al. () showed that cabergoline improved hypertension and glucose intolerance in patients with CD even when they were resistant to or escaped from treatment in terms of hormonal control.
A small trial in  patients with CD identified the greater efficacy of combined therapy with cabergoline and ketoconazole compared with either of the drugs alone, not only in terms of hormonal control but also in terms of improved glucose metabolism (): HbAc levels (median:  mmol/mol; range:  to  mmol/mol at baseline) did not drop significantly after  months of monotherapy (median:  mmol/mol; range:  to  mmol/mol), whereas a significant reduction was recorded after another  months of combined treatment with cabergoline and ketoconazole (median:  mmol/mol; range:  to  mmol/mol; P = . vs baseline and P = . vs monotherapy) (). These data may point to a synergistic glucoselowering effect from combined cabergoline and ketoconazole.
Nuclear receptor ligands
The nuclear receptor ligands include the PPAR-g agonists and the retinoic acid receptor agonists ().
Thiazolidinediones are agonists of PPAR-g, a nuclear receptor strongly expressed in adipose tissue-and to a lesser extent in muscle, the liver, b-cells, the vascular endothelium, and macrophages-that mediates different functions related to metabolism and cell growth, including the regulation of glucose metabolism (, ). PPAR-g activation promotes adipogenesis, insulin sensitivity, and tissue glucose uptake in a tissuespecific manner; it reduces hepatic gluconeogenesis and may improve B-cell viability (, ). Preadipocyte differentiation into new, small, insulin-sensitive adipocytes as a result of PPAR-g activation reduced circulating levels of free fatty acids and lipid accumulation in the skeletal muscle and liver, favoring glucose utilization and restricting the availability of free fatty acids as an energy source for hepatic gluconeogenesis ().
PPAR-g is also expressed in human ACTH-secreting adenomas, and thiazolidinediones have produced antiproliferative effects on corticotropinomas under experimental conditions (). The use of thiazolidinediones in hypercortisolism may be of interest in view of their potential antiproliferative and antidiabetic efficacy. However, clinical studies in CD patients have so far failed to reproduce the success observed in vitro and in mouse models, so these drugs are not currently used in clinical practice (, ).
Retinoic acid was shown to reduce hormone levels and tumor size in animal models of CD (). Some recent prospective clinical studies with retinoic acid up to  mg daily focused on its potential role in normalizing UFC in patients with CD, with concomitant improvement in glucose levels (, ), but few data are available as yet.
SST analogues ACTH-secreting adenomas express several somatostatin receptors (SSTRs) including SSTR and SSTR, which are involved in regulating ACTH release. There is evidence of GC excess causing a downregulation in SSTR expression, counteracting the antisecretory activity of classic SST analogues (octreotide and lanreotide) (). SST analogues can also inhibit insulin secretion () and may further impair glucose metabolism in patients with persistent hypercortisolism.
Pasireotide Pasireotide (SOM ) is a novel multireceptor SST analogue that was recently approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of adult patients with CD (, ). Pasireotide has a high affinity for binding four of the five known SST receptor subtypes (SSTRs  to  and SSTR ), and it has a -fold greater affinity for SSTR than octreotide (). SSTR expression on ACTH-secreting adenomas is not influenced by GC excess, and pasireotide was shown to control cortisol levels and improve clinical signs in patients with CD (, , ).
Compared with other SST analogues, however, pasireotide is more likely to cause hyperglycemia or overt DM as a side effect (, , -). In fact, SSTR is also involved in regulating insulin production by pancreatic B-cells, with inhibitory effects (, ).
The pathophysiology of pasireotide-induced hyperglycemia was investigated in mechanistic studies conducted in healthy volunteers (-). The shortterm continuous administration of increasing doses of pasireotide in these healthy subjects increased blood glucose levels associated with decreased insulin secretion (), with no significant change in glucagon output (). A significant inhibitory effect was demonstrated on intestinal GLP- and GIP secretion as well, whereas hepatic and peripheral insulin sensitivity was unaffected by pasireotide (, ). In CS patients, inhibiting insulin secretion may further worsen their glucose metabolism because they lack a potential mechanism to compensate for IR. Another potential problem with pasireotide is its effects on the GH/IGF-I axis, which-added to the inhibitory effects of GCs-could predispose patients to GH deficiency, contributing to the onset of metabolic alterations (, ).
Regarding patients with CD, pasireotide-induced hyperglycemia was reported in up to % of subjects () in a phase  clinical trial, a significantly higher rate than in patients treated with first-generation SST analogues. In addition, % of patients discontinued this treatment because of hyperglycemia-related adverse events or uncontrolled DM, though no cases of diabetic ketoacidosis or nonketotic hyperosmolar hyperglycemia were reported. Mean HbAc levels rose .% to .% from baseline after  months of pasireotide. At baseline,  patients (%) had DM and  (%) had prediabetes. At study end,  of the  patients without DM at baseline (%) had HbAc levels of .% or more. Despite the decline in cortisol levels, blood glucose and HbAc levels increased soon after pasireotide treatment was started, and a new glucose-lowering drug was prescribed for % of patients ().
It is possible, however, that controlling hypercortisolism with pasireotide may provide a more favorable outcome in terms of glucose metabolism after long-term treatment, as reported in some cases (, ).
In a recent retrospective, single-center study analyzing the -year experience of  patients with CD who were treated with pasireotide both in randomized trials and in clinical practice (), the glucose profile became worse in all but one of the patients. The rate of DM rose from % of patients ( of ) at baseline to % of patients ( of ) at last follow-up. New-onset DM was recorded in % of patients ( of ) with initially normal glucose tolerance and in % of patients ( of ) with a prediabetic state at baseline. Glucose and HbAc levels increased soon after pasireotide treatment was started (within the first  months) but stabilized after glucose-lowering drugs were initiated. In  patients not given glucoselowering medication at baseline, at least one such drug was prescribed during the pasireotide treatment in eight of these patients (%); all but two of these patients achieved satisfactory glycemic control. No association was found between UFC response and glycemic control during pasireotide treatment. Patients who experienced worsening glucose metabolism while receiving pasireotide treatment had significantly higher body weight, body mass index, and waist circumference at baseline ().
Considering the coexistence of SSTR and dopamine receptors in human ACTH-secreting adenomas, combination treatment with pasireotide and dopaminergic drugs may be justified. In a recent study, adding cabergoline to pasireotide improved control of hypercortisolism, with responders increasing from % to % (); the addition of ketoconazole further improved the control rate to % of patients. Although no data are available on the effects of this drug combination on glucose metabolism, concomitant D  dopamine receptor agonism presumably provided partial protection against the potentially negative effects of SSTR modulators (, , ); however, further studies are needed to test this hypothesis.
Given the pathophysiology of pasireotide-induced hyperglycemia, which is related to diminished secretion of incretin hormones, new antidiabetic agents such as dipeptidyl peptidase- inhibitors (e.g., sitagliptin, vildagliptin, saxagliptin, linagliptin) and GLP- receptor agonists (GLP- RAs; e.g., liraglutide, exenatide) are worth considering in this setting () .
No interventional studies have been conducted in CD patients with hyperglycemia secondary to the use of pasireotide, and the only available data concern the short-term effects of several antidiabetic drugs on pasireotide-induced hyperglycemia in healthy volunteers. In one study that explored incretin use in healthy individuals treated with pasireotide, an OGTT was performed before and after  week of randomized pasireotide  mg bis in die (bid) alone or coadministered with oral metformin  mg bid, nateglinide  mg ter in die (tid), vildagliptin  mg bid, or liraglutide . mg quaque die (qd). After  week, post-OGTT plasma glucose AUC increased by % with pasireotide and was reduced by %, %, %, and % with the coadministration of metformin, nateglinide, vildagliptin, and liraglutide, respectively ().
A group of experts on CD and DM advanced some recommendations on how to approach and manage the issue of pasireotide-induced hyperglycemia (). First, patients receiving pasireotide therapy should be carefully trained and accurately assessed in terms of their glucose metabolism at baseline. Then, close monitoring of their blood glucose profile and HbAc levels is essential (, ). Those with normal glucose metabolism before pasireotide treatment should monitor their own fasting and postprandial glucose levels by taking several blood glucose measurements a day (e.g., before and  hours after every meal) on  days in the first week and  day a week thereafter. Patients with IFG and/or IGT or receiving treatment for known overt DM should be closely monitored daily at the start of pasireotide treatment, and any antidiabetic drugs should be adjusted appropriately ().
In patients with effective control of cortisol hypersecretion but persistently altered glucose metabolism while "Treatment for diabetes mellitus is mandatory in patients whose Cushing syndrome is not cured with surgery." receiving pasireotide, concomitant antidiabetic treatment should be added before considering their withdrawal from pasireotide, given the difficulty of finding effective alternative treatments for hypercortisolism.
The management of pasireotide-induced hyperglycemia should be based on currently recommended treatment algorithms for type  DM (). First, patient education is mandatory and should include dietary changes and exercise. In patients with evidence of IR, any necessary treatment should begin with metformin as first-line therapy unless contraindicated or not tolerated (-). As a second step, treatment should preferentially address the two pathophysiological mechanisms involved in pasireotide-related hyperglycemia (i.e., a decrease in insulin secretion and an incretin response). Thus, combination therapy with incretin-based treatment is suggested when glycemic control is not achieved or maintained with metformin alone. GLP- RAs appear to be superior in terms of their glucose-lowering effect. If blood glucose levels are still not controlled, then insulin therapy may be required (, ).
Sulfonylureas or PPAR-g agonist treatments may be feasible as well but are not recommended. The former cause weight gain and carry a risk of hypoglycemia (due to glucose-independent insulin secretion), and the latter have been associated with an increase in body weight, fluid retention, and bone fractures, even though thiazolidinediones may theoretically control both hyperglycemia and hypercortisolism ().
Antidiabetic Therapy in CS Patients
Although GCs are well known to induce DM, no studies have specifically investigated the role of antidiabetic therapy in the treatment of hyperglycemia in patients with endogenous CS, and few studies have reported the effects of some antidiabetic agents in exogenous GC-induced hyperglycemia. So for both exogenous and endogenous CS, there is a dearth of evidence regarding the optimal treatment of impaired glucose metabolism, and recommendations are based largely on current best practice ().
Exogenous CS
In patients taking GCs, the risk of DM and other complications correlates with the dose and the duration of therapy (-), so drug exposure should be limited as far as possible. Lifestyle changes (a low-calorie diet and adequate physical activity) should be recommended as a preventive measure for all patients treated with GCs (). For patients developing GC-induced hyperglycemia, first-line treatment should include drugs that increase insulin sensitivity, such as metformin, and/or postprandial insulin secretion, such as dipeptidyl peptidase- inhibitors, GLP- RAs, sulfonylureas, or glinides. Among the insulin sensitizers, thiazolidinediones are not recommended as a first-line option because they may raise the risk of heart failure, bone loss, and fractures (-).
Insulin analogues may be needed to correct hyperglycemia in patients with uncontrolled DM despite oral hypoglycemic agents. GCs mainly increase postprandial glucose levels, so short-acting prandial insulin is often worth considering initially (). A basal-bolus approach may then be adopted in patients with more pronounced glucose metabolism impairments, bearing in mind that GC-treated patients need more prandial than basal insulin (usually % of their total insulin as a prandial dose and % as a basal dose) (). The daily insulin dose needed per kilogram of body weight depends on the corticosteroid dosage (). Neutral Protamine Hagedorn (NPH) insulin or long-acting analogues can be used in these patients as well. In a retrospective study comparing NPH insulin and glargine in hospitalized patients treated with prednisone, the two types of insulin were comparable in terms of efficacy and hypoglycemic risk, and a lower dose was used in the group treated with NPH (). Insulin should be considered first-line therapy for patients with DM given short-term or occasional high-dose GC treatments because of its rapid action compared with oral antidiabetic agents and its easy upward and downward dose adjustability to suit a patient's needs (, ).
Some authors recently reported the efficacy of GLP- RAs in treating GC-induced glucose intolerance. The GLP- RA exenatide was shown to antagonize the acute effects of prednisone on glucose tolerance and b-cell function in healthy humans; continuous intravenous infusions of exenatide significantly improved GCinduced hyperglycemia, restoring initial insulin secretion and reducing glucagon concentrations (). It has consequently been suggested that GLP- analogues can prevent postprandial hyperglycemia in steroid-induced DM (). Matsuo et al. () reported on the successful use of exenatide in four patients with type  DM and worsening glycemic control due to GCs. Van Genugten et al. () performed a randomized, placebocontrolled,  3  factorial, double-blind clinical trial in men with metabolic syndrome but no DM taking prednisolone plus sitagliptin (n = ), or prednisolone (n = ) or sitagliptin alone (n = ), or placebo (n = ) for  days. They found that adding sitagliptin improved various aspects of pancreatic islet cell function, preventing reduction in the first and second phases of glucose-stimulated C-peptide secretion and postprandial hyperglucagonemia ().
Endogenous CS
No research has been conducted on the use of antidiabetic therapy for glycemic control in patients with endogenous CS, and the literature contains only expert opinions based on current clinical practice and algorithms used for type  DM. In the acute setting, in patients with severe disease whose hyperglycemia demands prompt management, insulin treatment is often needed in the form of insulin infusion, prandial insulin, or basal-bolus regimens, associated with rapidacting cortisol-lowering therapy (e.g., metyrapone), to achieve glycemic control within days or weeks (). In the chronic setting, the priority is to achieve long-term control as reflected by HbAc levels (). Treatment of DM is mandatory in patients whose CS is not cured with surgery and is also important in patients with active hypercortisolism awaiting surgery to minimize the risks associated with anesthesia and postoperative complications; in fact, sustained hypercortisolism and uncontrolled diabetes are both important risk factors for infections after surgery (, , ). In this setting, oral insulin sensitizers (especially metformin) are first-line therapy in combination with cortisol-lowering agents, considering the preponderant effect of hypercortisolism on IR. Some patients may nonetheless need insulin therapy or other oral agents (). Close monitoring is needed when cortisol levels fall (e.g., after pituitary radiotherapy or in cyclical disease) because it is often necessary to reduce the dosage of hypoglycemic agents to avoid the risk of hypoglycemia. Little is known about the use of incretin-based therapy in endogenous CS, but one study showed that intravenous GLP- RAs reduced plasma glucose levels by stimulating insulin secretion and suppressing glucagon secretion in a patient with DM caused by CD ().
Potential Future Directions in the Management of Hyperglycemia in CS Patients
Research into drug therapies for DM continues, and numerous molecules are currently being investigated. Some classes of drugs under investigation in patients or animal models, though not tested in the specific setting of GC-induced diabetes, may be of particular interest in relation to the latter condition because of their particular mechanism of action.
11b-HSD1 inhibitors b-HSD controls the production of active GCs and has been proposed as a new target for the treatment of type  DM. More than  new compounds targeting b-HSD have been developed (). One of the most studied, INCB, completely inhibited b-HSD for  hours after its administration (, ). This drug was found to improve insulin sensitivity, reduce HbAc by .% ( mmol/mol), improve lipid profiles, and lower body weight during a -week randomized, phase , double-blind, placebocontrolled study in patients with type  DM inadequately controlled by metformin monotherapy (). However, the efficacy reported with b-HSD inhibitors as antidiabetic agents has been low; although these agents should theoretically restrict cortisol production in the liver and adipose tissue, a compensatory increase in ACTH may give rise to escape phenomena. Several phase  and  clinical trials are in progress.
Osteocalcin
A potential alternative therapeutic weapon may be osteocalcin, a bone-derived hormone that, in its uncarboxylated form (GluOC), plays an important part in glucose and energy metabolism, favoring b-cell proliferation, insulin expression, and secretion by pancreatic b-cells and sensitivity to insulin in peripheral tissues (). Excessive and prolonged exposure of bones to GCs in a mouse model was reported to suppress the synthesis and release of osteocalcin, contributing to a defective glucose metabolism (, ).
GluOC administered by intraperitoneal injection reportedly prevented obesity and restored insulin sensitivity and glucose tolerance in mice fed an obesogenic diet (). Other authors found that the beneficial effects of GluOC on glucose metabolism were partly mediated by GLP- () and that oral GluOC was as effective as peritoneal injection in mice ().
Selective GCR modulators
In the setting of exogenous CS due to the use of GCs as anti-inflammatory or immunomodulatory therapy for various diseases, development of new synthetic GCR modulators with the efficacy of a GC but without its side effects has been attracting interest.
GCR, the site of action for GCs, is a nuclear receptor that influences gene expression via a number of mechanisms, most notably transactivation, via direct binding to GC-responsive elements in the DNA, and transrepression, whereby activated GCR does not bind DNA but does interfere with the activation and/or activity of other DNA-bound transcription factors (, ). Cortisol is the natural ligand for GCR in humans, and the binding of cortisol or other synthetic GCs results in metabolic and anti-inflammatory effects. The broad metabolic effects are responsible for the undesirable side effect profile associated with the administration of GCs, including osteoporosis and DM. Because most of the metabolic side effects mediated by GCR are via transactivation, whereas most of the desired anti-inflammatory effects are via transrepression, efforts have been made to separate these two modes of GCR activity.
PF  is one of such new synthetic GCR modulators, also called "dissociated agonists of GCR" (DAGR), being developed to retain the antiinflammatory efficacy of GCs while reducing their unwanted effects, by virtue of this compound's differential effects on various molecular GC targets (genes containing GREs vs GCR-associated transcription factors, including AP). PF  is under investigation in patients with rheumatoid arthritis ().
Conclusions
In conclusion, the lack of studies on the effects of different antidiabetic agents in CS patients with altered glucose homeostasis has complicated development of guidelines on an optimal antidiabetic strategy for such patients. Further randomized prospective studies are needed to investigate the role of classic and new antidiabetic drugs in controlling or preventing hyperglycemia in patients with endogenous and exogenous hypercortisolism. Meanwhile, impaired glucose metabolism in CS patients should be managed in much the same way as type  DM.
